Mode AGC

ModeX Therapeutics is a clinical-stage biotechnology company focused on developing next-generation multispecific antibodies for the treatment of cancer and infectious diseases. The company's proprietary MSTAR platform enables the rapid design and production of complex proteins that can engage multiple targets simultaneously, potentially overcoming the limitations of traditional monoclonal and bispecific antibodies. ModeX was founded by a team of industry veterans with extensive experience in drug development and was acquired by OPKO Health in 2022 to bolster its biologics pipeline. Their lead programs focus on high-impact areas including oncology and viral pathogens.